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Introduction {#sec1}
============

Dengue virus (DENV) is a mosquito-borne *Flavivirus* with a single-stranded RNA genome that causes an estimated 390 million infections and up to 96 million dengue cases worldwide every year ([@bib4]). There are four closely related serotypes of DENV (DENV-1 to DENV-4), each of which encodes three structural proteins (Capsid \[C\], pre-Membrane/Membrane \[prM/M\], and Envelope \[E\]) and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). Infections with DENV can result in a spectrum of clinical manifestations, ranging from asymptomatic infection to the debilitating acute febrile illness, dengue fever (DF), to the life-threatening dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) ([@bib63]). Major determinants of dengue pathogenesis include virulence of the infecting DENV strain, host genetic factors, and pre-existing host immune responses from prior infection(s) with a different DENV serotype ([@bib22], [@bib33], [@bib38], [@bib40], [@bib45]). In sequential infections, disease severity appears to be determined by a complex interplay of protective and enhancing components from pre-existing immunity to viral antigens ([@bib21], [@bib43], [@bib49]). Such intricacies of the human immune response to DENV infection have made it difficult not only to identify the precise mechanisms that trigger progression to severe disease but also to engineer vaccines and therapeutics for combating the disease.

Replication of DENV within each host produces a population of genetically related but distinct genomes (referred to as intrahost diversity) due to the error-prone nature of the viral replicase, the RNA-dependent RNA polymerase (RdRP) ([@bib14]). These intrahost variants are thought to serve as templates on which evolutionary mechanisms act to shape variation at the consensus level between hosts (i.e., interhost diversity), leading to the emergence of genetically distinct strains and genotypes of DENV. Genetic variations in intrahost populations have been proposed to influence disease outcome and pathogenesis in chronic human infections with RNA viruses such as HIV and hepatitis C virus (HCV) ([@bib15], [@bib27], [@bib30], [@bib35], [@bib56]), which provide considerable time frames (months to years) for discernible virus evolution in response to intrahost selection pressures. Similar observations have also been reported in chronic infections with influenza virus and norovirus, viruses that are usually associated with acute infections ([@bib5], [@bib10], [@bib48], [@bib59]). These studies have characterized the emergence of individual variants associated with immune evasion or drug resistance. Unlike chronic infections, only a handful of studies have reported on the evolutionary mechanisms and viral genetics driving virus evolution in acute human infections such as Ebola ([@bib17], [@bib39]), chikungunya ([@bib55]), influenza A ([@bib54]), Middle East respiratory syndrome ([@bib42]), and dengue ([@bib41], [@bib47], [@bib51], [@bib52], [@bib58]), where virus evolution is severely constrained by time (days to weeks). Consequently, limited information exists about the fitness and pathogenesis profiles of individual intrahost DENV variants that emerge in acute human infections. Information on intrahost viral diversity can provide new perspectives in assessing infection outcome, disease pathogenesis, and vaccine or therapeutic efficacy in individuals with dengue or other closely related viral infections such as Zika.

In this study, we employ a whole-genome segmented amplification approach coupled with high-throughput sequencing to profile intrahost viral diversity across the entire coding region of the DENV-3 genome with considerable depth of coverage. Using snapshots of DENV-3 intrahost diversity in 31 plasma and 68 peripheral blood mononuclear cell (PBMC) samples from 77 individuals (including 22 with paired plasma and PBMC samples) enrolled in a prospective pediatric hospital-based study in Nicaragua, we demonstrate that DENV-3 diversification in human acute dengue (microevolution) is shaped by convergent selection pressures, including pre-existing immunity, and possibly by replication in sites other than PBMCs, while it is constrained by severe defects in replicative ability.

Results and Discussion {#sec2}
======================

Samples and Methods {#sec2.1}
-------------------

All PBMC and plasma samples used in this study were collected on the first day of presentation from individuals aged 6 months to 14 years with primary (1°; 53 samples) or secondary (2°; 46 samples) acute, symptomatic DENV-3 infection during the 2009--2010 epidemic season in Managua, Nicaragua ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}) ([@bib36]). The majority of PBMC (82%) and plasma (91%) samples were from individuals who presented with DF. The rest of the PBMC (18%) and plasma (9%) samples were from individuals who presented with DHF/DSS. Supporting clinical information is provided in [Table S1](#mmc1){ref-type="supplementary-material"}.Table 1Summary of Samples Used in This StudySample Type[a](#tblfn1){ref-type="table-fn"}Year of CollectionDisease SeverityImmune StatusNo. of Samples[b](#tblfn2){ref-type="table-fn"}No. of Paired Samples[b](#tblfn2){ref-type="table-fn"}PBMCs2009--2010DFprimary3211secondary239DHF/DSSprimary50secondary82Plasma2009--2010DFprimary1611secondary139DHF/DSSprimary00secondary22[^3][^4]

The DENV-3 genome was amplified via reverse transcription and PCR using sequence-specific primer pairs to generate 12 overlapping amplicons per sample ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Multiplexed libraries for high-throughput sequencing were constructed from pooled amplicon mixes and sequenced on an Illumina HiSeq 2000 platform to yield 150-nucleotide (nt) paired-end reads in forward (read 1) and reverse (read 2) orientations. Reference genomes were reconstructed for each sample using *Bowtie2* ([@bib29]) and *SAMtools* ([@bib31]), and in-house python scripts were used to calculate variation at the nucleotide, codon, and amino acid levels for each locus in the DENV-3 coding region (see [STAR Methods](#sec3){ref-type="sec"}). After filtering for coverage (≥1,000 reads) and Sanger quality scores (≥30), median coverage per codon locus was 22,975 and 20,024 for read 1 and read 2 datasets, respectively. Only samples with ≥50% coverage of the DENV-3 genome were retained for downstream analyses; 68 PBMC and 31 plasma samples from 77 individuals, including paired PBMC-plasma datasets from 22 individuals, passed the threshold for genome coverage. Coding-region coverage in these samples varied between 50.7% and 99.9% (median of 98.9%) for both read 1 and read 2 datasets combined ([Table S1](#mmc1){ref-type="supplementary-material"}).

Percent variant diversity at nucleotide, codon, and amino acid loci was calculated as the percent of reads spanning each coordinate that was different from consensus. Nucleotide- and codon-level diversities provide aggregate measures of both non-synonymous and synonymous mutations (i.e., mutations that do and do not change amino acid encoding, respectively), while amino acid diversity only captures non-synonymous mutations. In our study, variant abundances of ≥1.0% were reproducible across replicates (see [STAR Methods](#sec3){ref-type="sec"}) and were considered variants of high confidence. Unless otherwise specified, we used high-confidence variants for investigating diversity patterns. Samples from both sexes were included in all intrahost diversity comparisons; no significant differences between sexes were observed for any of the calculated DENV-3 intrahost diversity metrics (data not shown).

Intrahost Immune Pressures Shape DENV-3 Diversity in Acute Human Infections {#sec2.2}
---------------------------------------------------------------------------

We evaluated snapshots of intrahost diversity in samples from distinct subsets of individuals with 1° (53 samples) or 2° (46 samples) dengue to assess the effects of immune-driven selection pressures on intrahost DENV evolution. We compared the percent loci per protein that are variant in any sample between 1° and 2° dengue and found significantly fewer unique variant loci in 2° dengue cases, both in PBMC ([Figure 1](#fig1){ref-type="fig"} A; left panel, p \< 0.001) and plasma ([Figure 1](#fig1){ref-type="fig"}A; right panel, p \< 0.01) samples. These observations were not due to systematic disparities in the yields of viral RNA, since measures of genome equivalents (GE) per milliliter of extracted viral RNA were not significantly different between 1° and 2° cases for both PBMC and plasma samples ([Figure 1](#fig1){ref-type="fig"}B; left and right panels). Thus, DENV-3 appears to be evolving at fewer distinct loci genome-wide in 2° dengue compared with 1° dengue, suggesting that virus evolution is constrained by pre-existing immune pressures in 2° dengue. In addition, we examined the locations of unique variant loci on the exposed and membrane-associated surfaces of the E protein, which is a prominent target for antibody-mediated immunity in human dengue. We detected fewer unique variant loci across all samples in 2° dengue cases compared with 1° cases ([Figure 1](#fig1){ref-type="fig"}C; top and bottom panels) on both the exposed and the membrane-associated surfaces of E; much of this difference was contributed by PBMC-specific variant loci. Thus, consistent with genome-wide differences between 1° and 2° dengue, the breadth of the viral variant repertoire in E appears to be reduced in 2° dengue compared with 1° dengue. Such global differences in viral composition between naive individuals and individuals with pre-existing immunity to DENV indicate that the extent of diversity in the intrahost DENV-3 population is directed by the immune repertoire during acute dengue in humans. Further studies investigating particular epitopes will help resolve the specificities of pre-existing immune pressures contributing to differential rates of viral microevolution in 1° and 2° dengue.Figure 1DENV-3 Intrahost Diversity Is Shaped by Selection Pressures(A) Percent unique loci per protein with amino acid diversity, calculated as the percent of amino acids in a protein that show ≥1% variation, in PBMC (left panel) and plasma (right panel) samples from 53 individuals with 1° and 46 individuals with 2° dengue. ^∗^p ≤ 0.01, ^∗∗^p ≤ 0.001 (Wilcoxon signed-rank test). Each line represents one protein.(B) Comparisons of genome equivalents per milliliter (GE/mL) of extracted RNA in 53 1° and 46 2° cases from PBMC (left panel) and plasma (right panel) samples, median ± SD, boxes represent 25^th^ and 75^th^ percentiles and whiskers are 10^th^ and 90^th^ percentiles. n.s., non-significant (Wilcoxon test for unpaired samples).(C) All loci with ≥1% variation at the amino acid level, superimposed on the exposed surface (left panel) or the membrane-associated surface (right panel) of the DENV-3 E protein homodimer (PDB: [1UZG](pdb:1UZG){#intref0045}). Amino acids are colored according to whether they exhibit diversity in PBMC samples only (PBMCs, red), in plasma samples only (Plasma, blue), or in both PBMCs and plasma (Both, green). Data are shown separately for 53 1° (top panel) and 46 2° (bottom panel) dengue cases. *EDIa/b*, *EDIIa/b*, *EDIIIa/b* represent E domains I, II, and III from monomer chains a and b, respectively.(D) Percent amino acid variants for loci that exhibit diversity in PBMCs only (PBMCs), compared with loci that exhibit diversity in both PBMCs and plasma (Both), median ± SD, boxes represent 25^th^ and 75^th^ percentiles and whiskers are 10^th^ and 90^th^ percentiles. In the left panel, the y axis represents the percent abundance of non-synonymous variants in PBMCs. In the right panel, the y axis represents the percent abundance of synonymous variants in PBMCs. ^∗∗^p ≤ 0.0001 (Wilcoxon test), *n* = 22 paired PBMC and plasma samples.(E) Protein-specific comparisons of percent amino acid variants in 22 paired PBMC and plasma samples, colored by whether individual loci display ≥1% amino acid diversity in PBMC samples only (yellow), in plasma samples only (red), or in both PBMC and plasma samples (green). Data are shown for the two proteins (prM/M and NS3) that exhibit significant differences in % amino acid (AA) variants between PBMCs and plasma. All other proteins (including E, which is shown as an example) exhibit no significant differences in % AA variants between PBMCs and plasma. ^∗∗^p ≤ 0.0001, n.s., non-significant (Wilcoxon signed-rank test).(F) Comparisons of genome equivalents per milliliter (GE/mL) of extracted RNA in 12 paired PBMC and plasma samples. n.s., non-significant (Wilcoxon signed-rank test for paired samples).

Selection Pressures Shape DENV-3 Microevolution in Plasma {#sec2.3}
---------------------------------------------------------

We used patterns of DENV-3 intrahost diversity in paired PBMC and plasma samples from a subset of 22 individuals to assess the role of selection pressures mediated by human immune pathways or virion intracellular replicative success in shaping differences in DENV variants at the PBMC-plasma (i.e., intracellular-extracellular) interface and to explore the relative contributions from PBMCs and other potential viral replication sites to circulating virion populations in plasma.

We examined the percent abundance of non-synonymous variants in PBMCs and plasma, binning loci by whether variants were found at levels ≥1% in PBMCs only (PBMCs), or in both PBMC and plasma samples (Both). The median percent abundance of variant DENV-3 genomes that were found in PBMCs only was significantly lower than the median percent abundance of variant genomes found in both PBMCs and plasma, for both non-synonymous and synonymous variants ([Figure 1](#fig1){ref-type="fig"}D, left and right panels, p \< 0.0001). Thus, variants that appear in both PBMCs and plasma are more abundant than variants that are restricted to PBMCs, suggesting that DENV variants found in plasma have been selected based on their intracellular replicative success in PBMCs.

We also found evidence for immune-driven selection pressures shaping differences between plasma and PBMC DENV populations. In particular, significantly higher abundances for non-synonymous variants were observed in plasma compared with PBMCs for the prM/M and NS3 proteins ([Figure 1](#fig1){ref-type="fig"}E, p \< 0.0001), which are major targets of the human B cell and T cell immune responses, respectively ([@bib8], [@bib11], [@bib46], [@bib53], [@bib62]).

Furthermore, we observed many dissimilarities between PBMCs and plasma DENV populations that could not be attributed to replication defects or immune pressure mechanisms. For instance, minimal intersection was detected in the locations of variant loci on the highly antigenic E protein ([Figure 1](#fig1){ref-type="fig"}C, green loci), as well as in other proteins ([Figures 1](#fig1){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}A), inferred from the presence of fewer green lines representing loci with ≥1% amino acid variants in both PBMC and plasma samples, compared with orange and red lines representing loci with ≥1% amino acid variants in PBMC or plasma samples, respectively. These findings were not due to differences in the depth of sequencing coverage (data not shown), or in the number of viral copies used as input for generating sequencing libraries ([Figure S2](#mmc1){ref-type="supplementary-material"}B), because these parameters were comparable between paired PBMC and plasma samples. These observations of large-scale differences between plasma and PBMC DENV variant populations, when taken together with prior knowledge from human autopsy studies about the existence of significant non-PBMC compartments for viral replication in phagocytes, lymph node, spleen, alveolar macrophages in lung, and perivascular cells in brain ([@bib1], [@bib2], [@bib25]), suggest contribution to plasma DENV populations from replication compartments other than PBMCs.

Hotspots for DENV-3 Intrahost Diversity in Acute Human Dengue {#sec2.4}
-------------------------------------------------------------

We next sought to identify hotspots for intrahost viral diversity, defined as loci with detectable intrahost diversity in multiple hosts, in PBMC and plasma samples from individuals with DENV-3 infection. Hotspots may arise *de novo* within each host due to convergent selection pressures, or may be attributed to the co-transmission of wild-type (WT) and variant viruses within a host population. The probability of detecting diversity hotspots due to selection pressures has been assumed to be low in acute human dengue ([@bib12], [@bib32], [@bib41], [@bib58], [@bib60], [@bib61]), primarily because of the time constraint (8--14 days) on virus evolution within hosts.

We analyzed percent variant abundance together with percent prevalence of variants at each codon locus (depicted by the color and size of each data point) across the entire DENV-3 coding region and found that very few codon loci were hotspots for intrahost diversity in PBMC and plasma samples ([Figure 2](#fig2){ref-type="fig"} A, top and bottom panels, respectively). However, prominent hotspots for diversity were identified in the majority (59%--78%) of samples at three codon coordinates: (1, 2) 214 and 215, corresponding to amino acids 100 and 101 in the membrane portion of prM/M (hereafter prM~100~ and prM~101~), and (3) 595, corresponding to amino acid 315 in the highly conserved AB-loop region in E Domain III (E~315~) ([Figures 2](#fig2){ref-type="fig"}A and 2B). To confirm the presence of the more abundant E~315~ variant, we designed primers that specifically targeted and amplified either WT or E~315~ DENV RNA and validated the specificity of these primers using RNA from WT or E~315~ variant viruses ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We tested a subset of seven serum samples used in this study and were able to directly detect the E~315~ hotspot variant at various levels in all seven clinical samples ([Figure S3](#mmc1){ref-type="supplementary-material"}B).Figure 2Hotspots for Intrahost Diversity in the DENV-3 Genome(A) Percent intrahost codon diversity (y axis) across the coding region of DENV-3 (x axis) in 68 PBMC (top panel) and 31 plasma (bottom panel) samples; each data point is colored according to the number of samples in which ≥1% intrahost diversity is detected at that locus.(B) Major variants at the hotspot loci in prM/M (top) and E (bottom). Red asterisk, furin cleavage site.(C) Prevalence of major hotspot loci (i.e., loci with ≥1% variant abundance in ≥50% of samples) in 68 plasma (right panel) and 31 PBMC (left panel) samples in both read orientations (read 1 in yellow and read 2 in red).(D) Percent samples with diversity at each hotspot locus, shown for increasing cutoffs for percent intrahost codon diversity, in the 68 PBMC (left panel) and 31 plasma (right panel) datasets.(E) Average percent intrahost (yellow) and percent interhost (red) diversity in codon (left panel) or amino acid (right panel) coordinates for each hotspot locus. Interhost diversity was calculated across all global DENV-3 isolates for which full-genome sequences were available (*n* = 690).

The dominant variants at these hotspots were identical across samples ([Figure S2](#mmc1){ref-type="supplementary-material"}C) and exhibited altered amino acid sequence compared with consensus: (1) glycine to serine at prM~100~, (2) methionine to leucine at prM~101~, and (3) histidine to leucine at E~315~ ([Figure 2](#fig2){ref-type="fig"}B). prM~100~ and prM~101~ variants were significantly more prevalent in plasma (59.3% and 62.9%, respectively), compared with PBMC samples (2.9% and 1.4%, respectively) (p \< 0.0001, Fisher\'s exact test), while the E~315~ variant was highly prevalent in both PBMC (77.6%) and plasma (69.7%) samples ([Figure 2](#fig2){ref-type="fig"}C, average of read 1 and read 2 values). Hotspots detected were not PCR artifacts from the amplicon and library preparation (data not shown). Even at lower thresholds of ≥0.5% variant abundance, the prM~100~ and prM~101~ variants were only detected in a small number of PBMC samples (8.8%--13.2% of samples; [Figure 2](#fig2){ref-type="fig"}D). The E~315~ variants thus appear to originate in PBMCs (in addition to other cell types), whereas it is conceivable that the prM~100~ and prM~101~ variants arise in viral replication sites distinct from PBMCs, although we have not ruled out the possibility that these variants arose in PBMCs and are simply enriched in the extracellular environment. The prM~100,101~ and E~315~ variants constitute 2.2% and 1.9%, respectively, of an estimated 1.2 × 10^7^ GE/mL of circulating viral populations in plasma (extrapolated from [Figure 1](#fig1){ref-type="fig"}F; median yield of 1.2 × 10^6^ GE in 50 μL of RNA extracted from 100 μL of plasma) from individuals with detectable levels (≥1.0%) of these variants ([Figure S2](#mmc1){ref-type="supplementary-material"}C, median abundances). We also analyzed interhost diversity in 690 full-length DENV-3 consensus genomes (GenBank) and found that even though DENV-3 exhibited codon-level diversity at prM~100~ and E~315~ ([Figure 2](#fig2){ref-type="fig"}E, left panel, red bars), virus populations were invariant in the interhost amino acid sequence at all three hotspots ([Figure 2](#fig2){ref-type="fig"}E, right panel, red bars, and [Table S2](#mmc1){ref-type="supplementary-material"}), suggestive of macro-evolutionary (i.e., consensus-level) constraints at these loci. In addition to major hotspots, we detected several minor hotspots, defined as loci with 1.0% or higher variant abundance in ≥10% of samples, in both PBMC and plasma samples ([Figure S2](#mmc1){ref-type="supplementary-material"}D, all minor hotspots marked with ˆ). Of these minor hotspots, only one (codon 1071 in polyprotein) appeared to be shared between PBMC and plasma samples at a diversity threshold of 1.0% ([Figure S2](#mmc1){ref-type="supplementary-material"}D). All minor hotspots (loci marked with ˆ) exhibited interhost diversity at the codon level ([Figure S2](#mmc1){ref-type="supplementary-material"}E, left panel, red line, and [Table S2](#mmc1){ref-type="supplementary-material"}), but interhost amino acid diversity was only observed at five out of nine minor hotspots ([Figure S2](#mmc1){ref-type="supplementary-material"}E, right panel, red line, and [Table S2](#mmc1){ref-type="supplementary-material"}). Overall, our findings demonstrate that hotspots for intrahost viral diversity can be detected in acute human dengue. Furthermore, the presence of hotspot variants at macroevolutionarily conserved loci highlight the importance of host-specific selection pressures in DENV-3 intrahost evolution.

Convergent Evolution at Major Hotspot Loci {#sec2.5}
------------------------------------------

We next explored linkage patterns between polymorphisms in the sequences of reconstructed haplotypes spanning the prM~100,101~ and E~315~ major hotspot loci to identify whether (1) variants at the prM~100~ and prM~101~ hotspot loci were present on the same viral genome, and (2) viruses with variation at the prM~100,101~ and E~315~ hotspots arose *de novo* in different samples due to convergent selection pressures, or were present in multiple hosts due to co-transmission with consensus viral genomes. In samples with detectable levels of both prM variants at the population level, we observed that all haplotypes with the prM~100~ variant also included the prM~101~ variant (and vice versa), demonstrating that the prM variants were linked, i.e., present on the same variant viral genome ([Figure 3](#fig3){ref-type="fig"} A, red arrowheads). Moreover, we identified haplotypes with variants at only one prM hotspot ([Figure S2](#mmc1){ref-type="supplementary-material"}F), which implied that DENV-3 was evolving independently at each of the prM~100~ and prM~101~ hotspots. The prM~100,101~ variant thus appears to be the result of sequential evolution at prM~100~ and prM~101~ on the same viral genome. Our haplotype analysis also revealed significant interhost diversity at three loci proximal to the prM~100,101~ and E~315~ hotspots ([Figures 3](#fig3){ref-type="fig"}A and 3B; black arrowheads). Four different haplotypes with a wide range of frequencies were detected among the consensus genomes in our samples, each with unique combinations of nucleotide diversity at these loci ([Figures 3](#fig3){ref-type="fig"}A and 3B, and [Table S3](#mmc1){ref-type="supplementary-material"}). Nucleotides at all three polymorphic loci were 100% concordant between the dominant WT consensus genome and the prM/M or E variant genome for all samples ([Figures 3](#fig3){ref-type="fig"}A and 3B and [Table S3](#mmc1){ref-type="supplementary-material"}; variant genomes marked with ^∗^). This was true even for samples with low-frequency consensus haplotypes (C-A-T and A-G-G haplotypes for prM/M and E, respectively), and for samples in which mixed infections with multiple WT haplotypes were detected ([Figures 3](#fig3){ref-type="fig"}A and 3B; genomes marked with \#). The genetic concordance between WT and variant haplotypes in our samples strongly support the independent emergence and/or expansion of these hotspot variants within each individual, although we cannot completely exclude contributions from co-circulating variants at the prM~100,101~ and E~315~ loci. Taken together, our observations indicate that variants at the prM~100,101~ and E~315~ hotspot loci arose by convergent evolution during acute dengue, in at least four independent events, corresponding to the presence of the variants in four distinct haplotypes.Figure 3Sequence Diversity in Reconstructed Haplotypes Spanning the Intrahost Diversity Hotspots in prM/M and EColor-coded nucleotide diversity in regions flanking intrahost diversity hotspots in (A) prM/M and (B) E; each row represents a unique reconstructed haplotype with the hotspot variant in 8 PBMC/plasma samples for the *prM/M* hotspot and 39 PBMC/plasma samples for the *E* hotspot (samples delineated by thin white lines). Consensus haplotypes and their observed frequencies across all Nicaraguan samples are shown on the left, separated by thick white lines. Haplotypes with the prM~100,101~ and E~315~ variants are denoted with asterisks (^∗^), WT variant haplotypes distinct from the consensus haplotype are marked with \#, and underlined loci in B represent the AB-loop region containing the E hotspot. Red asterisk, furin cleavage site. Red arrowheads, prM and E hotspot variants. Black arrowheads, other variants present at \>1% abundance.

Replication Phenotypes and Origins of Hotspot Variants {#sec2.6}
------------------------------------------------------

The four-plasmid reverse genetics approach ([@bib34]) was used to engineer chimeric infectious clones containing non-structural genes from a 1989 Sri Lankan DENV-3 isolate (GenBank: [JQ411814.1](ncbi-n:JQ411814.1){#intref0010}) and either (1) Nicaraguan consensus sequence for the structural genes (WT), (2) WT Nicaraguan consensus with the Gly100Ser and Met101Leu mutations in the membrane portion of prM/M (prM~100,101~ mutant), or (3) WT Nicaraguan consensus with the His315Leu mutation in the AB loop in E (E~315~ mutant). We evaluated the replication phenotypes of WT and mutant viruses in C6/36 mosquito cells by directly competing each mutant virus with WT virus in co-infection experiments ([@bib44]). Viral RNA mixtures from the input and from cellular supernatants collected 3, 4, and 5 days post infection (d.p.i.) were sequenced by the Sanger method to capture ratios of WT and mutant nucleotides at the prM~100,101~ and E~315~ hotspots using the polySNP program. The replicative index, calculated as the log~2~ value of relative levels of WT and mutant viruses in the supernatant compared with relative levels in the input, was negative for prM~100,101~ or E~315~ mutant viruses at 3--5 d.p.i., indicating that both mutants were replication defective in C6/36 cells compared with WT ([Figure 4](#fig4){ref-type="fig"} A). In addition, we assessed the replication phenotypes of WT and mutant viruses in a human monocytic U937 cell line that expresses DC-SIGN, a co-receptor for DENV entry ([@bib57]) (U937-DC-SIGN). Single infections were performed in U937-DC-SIGN cells with 625 GE/cell each of WT, prM~100,101~, and E~315~ viruses. All three viruses were able to establish infection in U937-DC-SIGN cells; however, the percent of infected cells was considerably reduced in infections with prM~100,101~ and E~315~ variants compared with WT virus at 1, 2, and 3 d.p.i., as determined with both anti-E and anti-NS3 antibodies ([Figure 4](#fig4){ref-type="fig"}B, left and right panels, respectively). No revertants were detected at 3 d.p.i. with either variant (data not shown). The E~315~ variant also exhibited a temperature-sensitive (32°C versus 37°C) plaquing phenotype on baby hamster kidney (BHK-21) cells with better plaquing at 32°C, whereas the prM~100,101~ variant plaqued relatively well at 37°C ([Figure S4](#mmc1){ref-type="supplementary-material"}). Our results thus demonstrate that the prM~100,101~ and E~315~ mutant viruses establish infections in C6/36 mosquito cells, U937-DC-SIGN human cells, and in BHK-21 mammalian cells with considerably reduced efficiencies due to the deleterious effects of these mutations on viral replicative ability.Figure 4Phenotypic Differences between Wild-Type, prM~100,101~, and E~315~ Viruses(A) C6/36 cells were infected with a mixture containing WT virus and the prM~100,101~ (yellow) or E~315~ (red) mutant viruses. The replication index was measured as the log~2~ value of relative levels of mutant and WT genomes in the supernatant at 3--5 d.p.i., compared with the corresponding ratios in the input. A negative index indicates that the replicative ability of mutant virus is lower than WT virus.(B) U937-DC-SIGN cells were mock-infected (mock, blue) or infected with WT (aqua), prM~100,101~ (yellow), and E~315~ (red) viruses, fixed, and stained with anti-E (left panel) and anti-NS3 (right panel) antibodies at various time points post infection. All data points for (A and B) represent the average of two independent experiments, mean ± SD.

The prM~100,101~ and E~315~ mutant viruses do not exhibit any defects in entry and behave similar to WT virus, as demonstrated by directly comparing entry capabilities of the three viruses using U937-DC-SIGN cells at 37°C ([Figure S5](#mmc1){ref-type="supplementary-material"}), suggesting that the replication defect for both prM~100,101~ and E~315~ mutant viruses is downstream of virus entry. We do not anticipate that these mutations have a direct impact on viral RNA replication, as none of the DENV structural proteins, except RNA elements in the Capsid gene ([@bib6], [@bib7], [@bib9], [@bib16], [@bib50]), have been implicated in a direct role in RNA replication. In studies by [@bib65], mutations at prM~98~ in DENV-1 were shown to result in impaired prM processing and decreased viral infectivity. prM~100~ and prM~101~ are situated only 2--3 amino acids away from prM~98~, and given the absence of entry and replication defects, we hypothesize that the prM~100,101~ hotspot mutations likely impair prM processing and DENV infectivity, by a mechanism similar to prM~98~ ([@bib65]). Even though prM antibodies have been identified by several groups ([@bib3], [@bib11]), the immune pressures driving evolution at the prM/M locus are poorly understood, and the origin of the prM~100,101~ variant viruses remains elusive. In contrast, significantly more is known about the functionalities and antigenicity of loci in the E protein, and specifically the E~315~ locus. Previous studies have shown that E~315~ plays a pH-sensing role in mediating viral fusion with the endosome at the post-entry stage ([@bib37]), suggesting that viruses with the E~315~ hotspot mutation are likely impaired at the stage of viral membrane fusion with the endosomal membrane. Interestingly, the process of viral membrane fusion appears to be a significant target of anti-DENV antibodies during infection in humans, with fusion loop antibodies making up a significant proportion of the population of broadly reactive antibodies that are elicited during infection with DENV ([@bib18], [@bib28]). Given the convergent nature of the immune response and the prevalence of the E~315~ variant, it is conceivable that the E~315~ variant arose as an immune-escape variant to fusion loop antibodies. Indeed, [@bib18] demonstrated that after 11 cycles of passage in the presence of anti-fusion loop mAb 1A5, an escape mutation was isolated at E~317~ in DENV-2, further supporting our claim that immune pressures exerted by fusion loop antibodies played a key role in convergent selection for variants at the analogous E~315~ hotspot locus in DENV-3. Taken together, we conclude that the E~315~ hotspot variant, despite possibly possessing an immune-escape advantage, is constrained to the intrahost evolutionary system because of the severe defects associated with viral membrane fusion post entry.

Concluding Remarks {#sec2.7}
------------------

We have thus demonstrated that intrahost DENV-3 populations can rapidly and convergently evolve in acute human infections, with virus microevolution possibly shaped by viral replication compartments distinct from PBMCs, driven in part by immune selection pressures and constrained by replication defects at the macro-evolutionary scale. In particular, we identified a highly prevalent DENV variant (E~315~) that likely arose as an immune-escape variant in response to pressures exerted by fusion loop antibodies, yet was constrained by severe replicative defects likely incurred due to a deficiency in viral membrane fusion with the host endosome post entry. The identification of such convergent immune pressures that appear to result in the selection of prevalent immune-escape variants, especially ones that are constrained by replication defects or fitness costs, could be harnessed for intelligent selection of new candidates and targets for vaccine/drug design. Such snapshots of intrahost DENV diversity help to identify mechanisms driving virus microevolution in human dengue and provide new perspectives in assessing infection outcome, disease pathogenesis, and vaccine/therapeutic efficacy in individuals.

STAR★Methods {#sec3}
============

Key Resources Table {#sec3.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**anti-E (5D4)Hybridoma from ATCC5D4-11 (ATCC® HB-49™), RRID: CVCL_J928; [@bib24]anti-NS3 (E1D8)Hybridoma generated in Harris LaboratoryE1D8, [@bib2]**Bacterial and Virus Strains***E. coli* TOP10 competent cellsInvitrogenC4040-10**Biological Samples**PBMC and plasma samplesThis paper: [Table S1](#mmc1){ref-type="supplementary-material"}N/A**Chemicals, Peptides, and Recombinant Proteins**Kanamycin SulfateLife Technologies11815-024Chloramphenicol \>=98% (TLC)Sigma-AldrichC0378-25G**Critical Commercial Assays**RNeasy Mini kitQiagenCat No./ID: 74104QIAamp Viral RNA Mini KitQiagenCat No./ID: 52904QIAquick Gel Extraction KitQiagenCat No./ID: 28704Nextera XT DNA Sample Preparation KitIlluminaFC-131-1096SuperScript III One-Step RT-PCR SystemInvitrogen12574-035mMessage mMachine T7 KitLife TechnologyAM1344MMinElute Gel Extraction Kit (50) (70bp to 4kb)QiagenQia 28604**Deposited Data**Fastq files for all these samples have been deposited intoNCBI\'s Sequence Read ArchiveBioProject ID PRJNA394021**Experimental Models: Cell Lines**Baby hamster kidney cells (BHK-21 clone 15)Gift from B. Childs (Center for Vector-born Diseases, University of California, Davis, CA)N/AC6/36 cells, 37°C in 5% CO~2~.Gift from Dr. Ralph Baric, University of North Carolina, Chapel HillN/AU937-DC-SIGN cellsGift of Dr. Aravinda de Silva, University of North Carolina, Chapel HillN/A**Oligonucleotides**Sequences of primers used for amplifying the DENV-3 genome[Table S4](#mmc1){ref-type="supplementary-material"} of this paperN/ADV3Ewt_r: CGACCTTAATGAGTATTGTCCCATThis paperN/ADV3E^∗^\_r: CGACCTTAATGAGTATTGTCCCAaThis paperN/APP49_DENV3_32_F (GACTCGGAAGCTTGCTTAAC)This paperN/Aprimers (5'- GACTCGGAAGCTTGCTTAAC-3' and 5'-TATTGACAGGCTCCTCCTTCTTAG-3') designed to capture the prM~100,101~ and E~315~ hotspot lociThis paperN/ASequencing primer for prM~100,101:~ 5'-TCAATATGCTGAAACGCGTG-3'This paperN/ASequencing primer for E~315:~ 5'-CGGACAGGTTTGGATTTCAATG-3'This paperN/A**Recombinant DNA**plasmid A-DGift of Dr. Ralph Baric[@bib34]plasmid A Nicaraguan WTThis paperN/Aplasmid A Nicaraguan prM~100,101~This paperN/Aplasmid A Nicaraguan E~315~This paperN/A**Software and Algorithms**Bowtie2[@bib29]<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>Samtools[@bib31]<http://samtools.sourceforge.net/>ShoRAH[@bib64]<http://www.cbg.ethz.ch/software/shorah>

Contact for Reagent and Resource Sharing {#sec3.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Eva Harris (<eharris@berkeley.edu>).

Experimental Model and Subject Details {#sec3.3}
--------------------------------------

### Ethics Statement {#sec3.3.1}

All studies were approved by the Institutional Review Boards (IRBs) of the University of California, Berkeley, and of the Nicaraguan Ministry of Health. Written consent was obtained from the parents/legal guardians of all pediatric subjects. Assent was also obtained from subjects six years of age or older.

### Study Population {#sec3.3.2}

PBMC and plasma samples were obtained from subjects in an ongoing prospective hospital-based study of pediatric dengue in Nicaragua established in 1998 ([@bib23]), which enrolls patients who present with suspected dengue to the National Pediatric Reference Hospital in Managua, Nicaragua. Plasma and PBMCs are collected from patients for three sequential days during the acute phase of illness, at convalescence (days 14-28) and longitudinally for 18 months. Criteria for identifying dengue-positive cases and for classifying by immune status are as described ([@bib19], [@bib36]). Dengue cases are classified as DF, DHF, or DSS according to the 1997 WHO Dengue Guidelines ([@bib36], [@bib63]). Thirty-one plasma and 68 peripheral blood mononuclear cell (PBMC) samples from 77 individuals (including 22 with paired plasma and PBMC samples) were analyzed in this study. The gender identity as well as the age of the patients is listed in [Table S1](#mmc1){ref-type="supplementary-material"}. Extensive epidemiological and clinical data are available for these samples. The sample size for this study was determined by availability of pediatric patient samples for primary and secondary dengue cases caused by DENV-3 within a single endemic year (2009-2010). Subgroups within the 77 patients in the study were selected based on sample type (plasma versus PBMCs), clinical classification (for example, primary versus secondary dengue, Dengue Fever versus Dengue Hemorrhagic Fever and Dengue Shock Syndrome), or gene origin of variation (based on DENV-3 gene annotation).

### Cell Culture {#sec3.3.3}

Baby hamster kidney cells (BHK-21 clone 15) were maintained in αMEM (Gibco) supplemented with 5% heat-inactivated Fetal Bovine Serum (FBS; Gibco), 10 mM HEPES (Gibco), and 100 U/ml penicillin and 100 μg/ml streptomycin (Pen/Strep; Gibco) at 37°C in 5% CO~2~. C6/36 cells (gift of Dr. Ralph Baric) were maintained in MEM with HEPES supplemented with 10% heat-inactivated FBS, 1X non-essential amino acids (NEAA; Gibco), 2 mM L-glutamine (Gibco) and Pen/Strep at 32°C in 5% CO~2~. U937 cells expressing DC-SIGN (U937-DC-SIGN, gift of Dr. Aravinda de Silva) were maintained in RPMI 1640 medium (Gibco) supplemented with 5% FBS, 1% Pen/Strep and 1% HEPES at 37°C in 5% CO~2~.

Method Details {#sec3.4}
--------------

### RNA Extraction and DENV-3 Genome Amplification {#sec3.4.1}

A hybrid TRIzol/RNeasy protocol was developed for viral RNA recovery from PBMCs. Briefly, PBMCs were lysed in TRIzol (Life Technologies), and aqueous phase RNA was extracted after addition of chloroform. Next, 3.5 volumes of Buffer RLT (RNeasy Mini kit; Qiagen) and 2.5 volumes of 100% ethanol were added to the RNA solution, and the mixture was applied to an RNeasy column. All washes and RNA elutions were performed as described (RNeasy kit protocol). Viral RNA from plasma samples was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) as described in the manufacturer's protocol. RNA was eluted in 50 μl of RNase-free water containing linear polyacrylamide (1 μl; Life Technologies), carrier RNA (0.1 μl; Qiagen), and SUPERase-In (1 μl; Life Technologies). Twelve RT/PCR amplifications were set up for each sample, with various combinations of forward and reverse primers ([Table S4](#mmc1){ref-type="supplementary-material"}) and reagents from the SuperScript III One-Step RT-PCR System (Invitrogen). For each reaction, we used 5 ul of denatured RNA, 17.5 ul of a 2X reaction mix, 0.25 ul each of forward and reverse primers (100 uM), 0.7ul of the enzyme mix, and 11.3 ul of RNase-free water. DENV-3 RNA was reverse-transcribed (50°C for 60 minutes) and cDNA was amplified as follows: 1 cycle of denaturation (94°C for 2 minutes), 35 cycles of denaturation (94°C for 15 seconds), annealing (55°C for 30 seconds), and extension (68°C for 3 minutes), and a final extension step (68°C for 10 minutes)}. The conditions were identical for all amplicons except amplicon 4, for which the extension time was shortened to 1 minute. DENV-3 amplicons were purified on a 1% agarose gel, and DNA was recovered using the QIAquick Gel Extraction Kit (Qiagen). For each sample, PCR amplicons were pooled in equimolar ratios, and indexed libraries were prepared for high-throughput sequencing using the Nextera XT DNA Sample Preparation Kit (Illumina). Nextera XT libraries were pooled and sequenced for 150 cycles in two lanes on Illumina's HiSeq 2000 platform to generate paired-end datasets.

### Consensus Genome Imputation and Variant Analysis {#sec3.4.2}

Reads were segregated based on their forward (read 1) and reverse (read 2) indices. The paired-end datasets for reads 1 and 2 were analyzed separately for all samples.

#### Filtering for Read Quality {#sec3.4.2.1}

The Fastx toolkit (<http://hannonlab.cshl.edu/fastx_toolkit/>) was used to (a) trim reads with low quality (\<Q30) at the 3' end, (b) remove reads less than 50 nucleotides in length, and (c) only retain reads of high quality sequence (≥Q30) at ≥90% of read length.

#### Read Alignments and Variant Identification {#sec3.4.2.2}

We generated a DENV-3 consensus genome based on all sequenced Nicaraguan DENV-3 isolates from the 2009-2010 epidemic year (*n* = 108; NCBI Virus Variation Database). Read 1 and read 2 datasets for each sample were aligned to the Nicaraguan DENV-3 consensus genome using *Bowtie2* ([@bib29]). *SAMtools* ([@bib31]) was used to create a pileup file from the *Bowtie2* output, and pileup files were filtered based on a minimum read quality score of 30 and minimum coverage of 5 reads. Consensus genomes were created for each dataset using in-house scripts, and gaps were filled with Nicaraguan DENV-3 consensus sequences. All datasets were re-aligned to their corresponding consensus genomes using *Bowtie2,* and pileup files generated by *SAMtools* were filtered based on quality scores (≥30). Fastq files for all the sequences generated in this study have been deposited into NCBI\'s Sequence Read Archive, and can be accessed using BioProject ID PRJNA394021. In-house scripts were used to calculate percent variant abundance in nucleotide, codon and amino acid coordinates at all loci with a minimum coverage of 5 reads.

#### Threshold for Variant Abundance {#sec3.4.2.3}

Replicate amplicon libraries were analyzed in a pairwise manner to set abundance thresholds for high-confidence variant detection. In replicate amplicon libraries from four PBMC samples, all variants that were detected at an abundance of ≥0.5% in replicate A were also detected in replicate B ([Figure S1](#mmc1){ref-type="supplementary-material"}B, *left panels*) and *vice versa* (*data not shown*). However, the threshold for variant detection in both replicates was considerably higher for replicate libraries from the three serum samples (≥1.0%; [Figure S1](#mmc1){ref-type="supplementary-material"}B, *right panels*). Additionally, frequency distribution of loci by percent variant abundance in replicate B, for various thresholds of percent variant abundances in replicate A, revealed that concordance of 50% or higher between replicates was achieved at loci with ≥1.0% variant abundance in both PBMC and serum samples ([Figure S1](#mmc1){ref-type="supplementary-material"}C, *left and right panels*, respectively). For identifying variants, we implemented the following thresholds: (a) loci should have a minimum coverage of 1000 reads, (b) variant abundance must be ≥1%, and (c) variant cannot be in a primer-binding region.

#### Reconstructing Haplotypes {#sec3.4.2.4}

The software package *ShoRAH* ([@bib64]) was used to reconstruct 150 nucleotide-haplotypes spanning the prM~100,101~ and E~315~ hotspot loci. Only haplotypes with a reconstruction quality score of ≥0.9 were considered for diversity analysis.

### Generation of WT, prM~100,101~ and E~315~ DENV-3 Viruses {#sec3.4.3}

A four-plasmid infectious clone system (plasmids A-D; gift of Dr. Ralph Baric ([@bib34])) based on a Sri Lankan DENV-3 template was used to derive Nicaraguan WT DENV-3 and DENV-3 with mutations at the prM~100,101~ or E~315~ hotspot loci. We introduced four amino acid changes in the C, prM and E sequences in plasmid A (P27S, I286V, V361T and A609V in the DENV-3 polyprotein) to generate infectious clones that were identical in structural protein sequence to the Nicaraguan DENV-3 consensus genome ("WT"). The prM~100,101~ mutations were inserted by site-directed mutagenesis in plasmid A using the QuikChange site-directed mutagenesis kit (Stratagene). The E~315~ mutation was synthesized in the context of a plasmid A fragment spanning nucleotides 1-2034 of the DENV-3 genome (Bio Basic, Inc.). Infectious clones for WT, prM~100,101~ and E~315~ viruses were derived as described ([@bib34]), with some modifications. All plasmids were individually propagated in *E. coli* TOP10 competent cells (Invitrogen) and grown on LB plates with selective antibiotics (plasmid A encoding for WT, prM~100,101~ and E~315~ was selected with ampicillin, plasmids B and C with kanamycin, and plasmid D with chloramphenicol) at 30°C for 24 hours. Sequences of colony-purified plasmids were confirmed by Sanger sequencing, and restriction digests were set up as follows: plasmid A with SpeI, AhdI and BsmBI yielding a 2.0-kb fragment; plasmid B with BglI and BsmBI yielding a 1.1-kb fragment; plasmid C with BglI yielding a 3.9-kb fragment; and plasmid D with BglI and BsmbI yielding a 3.0-kb fragment. Fragments were gel-purified using a MinElute Gel Extraction Kit (Qiagen), mixed in equimolar ratios, and ligated with T4 ligase (NEB) for 2 hours at 16°C. Full-length transcripts of DENV-3 cDNA constructs were generated *in vitro* as described using the mMessage mMachine T7 Kit (Ambion) with the following modifications: (a) 20 μl reaction mixtures were supplemented with 2 μl of a 30 mM GTP stock, resulting in a 1.3:1 ratio of cap analog to GTP, and (b) the reaction was incubated at 37°C for 3 hours. For electroporation, DENV-3 transcripts were added to 400 μl of BHK cell suspension (1 x 10^7^ cells/ml in RNase-free PBS) in an electroporation cuvette, and pulsed once with 270 V (975 μF) in a Bio-Rad Gene Pulser II electroporator. The transfected BHK cells were grown in a 75 cm^2^ flask and incubated at 37°C for 5 days. For virus amplification, 2 ml of viral supernatant from BHK cells was used to infect C6/36 cells in a 75 cm^2^ flask, and 18 ml of C6/36 media (1X MEM + 2% FBS + 1% Pen/Strep + 1% NEAA + 1% L-Glutamine) was added to the cells. Supernatants were harvested five days post-infection, supplemented to 1X SPG (sucrose-phosphate-glutamate stabilizer, prepared in-house), clarified by centrifugation, and frozen at −80°C or passaged serially in C6/36 cells.

### Virus Titration {#sec3.4.4}

For plaque assays, ten-fold serial dilutions of virus culture supernatant (undiluted, and dilutions of 10^−1^ to 10^−5^) were added in duplicate to cultured BHK-21 cells in 24-well plates and incubated for 1 h at 37°C. After discarding the inoculum, the cells were overlaid with 1 ml of 0.8% carboxymethyl cellulose in MEM supplemented with 2% FBS and Pen/Strep. Plates were incubated for 4 days at 37°C in 5% CO~2~. Overlays were removed, cells were fixed with formalin and stained with 2.5% crystal violet in 30% ethanol, and plaque-forming units per ml (PFU/ml) were counted. For assaying temperature sensitivity, infections and post-infection incubations were performed at 32°C in 5% CO~2~, and plaques were counted 7 days p.i.. For quantitative RT-PCR (qRT-PCR), 18 μl-reactions were set up with 2 μl RNA, DENV-3 specific primers ([@bib26]), 0.1 μM DENV-3 probe ([@bib26]), and reagents from the Verso 1-Step qRT-PCR kit (Thermo Scientific). Reaction conditions were as follows: 1 cycle of reverse transcription (30 minutes at 50°C), 1 cycle of Thermo-Start activation (12.5 minutes at 95°C), and 40 cycles of denaturation (15 seconds at 95°C) and annealing/extension (1 minute at 60°C). A standard curve was used to calculate DENV-3 genome equivalents per ml (GE/ml) for each test sample.

### Relative Quantitation of Viruses by Sequencing {#sec3.4.5}

Viral RNA was amplified using reagents from the SuperScript III One-Step RT-PCR System, with primers (5'- GACTCGGAAGCTTGCTTAAC-3' and 5'-TATTGACAGGCTCCTCCTTCTTAG-3') designed to capture the prM~100,101~ and E~315~ hotspot loci. Amplicons were gel-purified and sequenced by the Sanger method using primers 5'-TCAATATGCTGAAACGCGTG-3' and 5'-CGGACAGGTTTGGATTTCAATG-3' for capturing chromatogram peak heights at the prM~100,101~ and E~315~ loci, respectively. Relative levels of WT and mutant viruses were calculated from quantitation of chromatogram peak heights at the hotspot loci corresponding to WT and mutant nucleotides using the PolySNP program ([@bib20]).

### Replication in C6/36 Cells {#sec3.4.6}

For each infection, we used six-well plates with 2 X 10^5^ C6/36 cells per well, and a virus mix containing 1000 GE/cell of WT and 1000 GE/cell of prM~100,101~ or E~315~ viruses (as determined by qRT-PCR) diluted in Hank's Balanced Salt Solution (HBSS; Gibco). One hundred μl of the virus mix was stored for assessing input ratios. C6/36 cells were infected with each virus mix for 2 h at 32°C in 5% CO~2~, washed with PBS, and incubated in MEM containing 2% FBS, 1% Pen/Strep, 1% NEAA and 1% L-Glutamine. Supernatants were collected from independent wells at 3, 4 and 5 d.p.i.. Viral RNA was extracted from supernatants and the input virus mix using the QIAamp Viral RNA kit (Qiagen). All experiments were performed in duplicate. Relative levels of WT and mutant viruses were estimated using Sanger sequencing and the polySNP program ([@bib20]).

### Replication in U937-DC-SIGN Cells {#sec3.4.7}

Infections were set up in 96-well plates with 5 x 10^4^ U937-DC-SIGN cells per well. Infections were performed with 625 GE/cell of WT, prM~100,101~ or E~315~ viruses, diluted in HBSS. Cells were infected with each virus mix for 2 h at 37°C in 5% CO~2~, washed and incubated in medium containing RPMI 1640, 2% FBS, 1% Pen/Strep and 1% HEPES for 24, 48 or 72 h at 37°C in 5% CO~2~. Cells were stained at room temperature with a 1:500 dilution of Zombie Aqua stain (BioLegend), fixed, permeabilized, and stained with a 1:250 dilution of an anti-E (5D4) ([@bib24]) monoclonal antibody conjugated to Texas Red and a 1:500 dilution of an anti-NS3 (E1D8) ([@bib2]) monoclonal antibody conjugated to APC. All experiments were performed in duplicate. The percent of infected cells was measured via flow cytometry on an LSR Fortessa cell analyzer (BD Biosciences), and the data were analyzed using FlowJo 8.8.7 software (TreeStar).

### RT-PCR from Serum {#sec3.4.8}

Reverse primers specific for WT or E~315~ mutant virus were designed as follows: primer WT (DV3Ewt_r: CGACCTTAATGAGTATTGTCCCAT); primer E~315~ (DV3E^∗^\_r: CGACCTTAATGAGTATTGTCCCAa). In combination with the forward primer PP49_DENV3_32_F (GACTCGGAAGCTTGCTTAAC), both primer sets generated an RT-PCR amplicon of 1,865bp. RT-PCR was carried out using SuperScript® III One-Step RT-PCR System with Platinum® Taq High Fidelity (Invitrogen). The RT-PCR products were visualized using an agarose gel (1%).

### Entry Assays {#sec3.4.9}

The entry assay was performed as previously described ([@bib13]) with slight modifications. Specifically, 10μl of U937-DC-SIGN cells (1x10^7^ cells/ml, total of 1x10^5^ cells) was aliquoted into microcentrifuge tubes in triplicate, mixed with WT virus (multiplicity of infection of 0.5), E~315~ variant virus or prM~100,101~ variant virus diluted in 240μl of U937-DC-SIGN culture medium, and incubated at 37°C for 2 hours with occasional agitation to avoid pelleting. All samples were then iced and washed three times with 500μl of U937-DC-SIGN culture medium at 4°C, and washed twice with 500μl PBS at 4°C. Then 350μl of lysis buffer was added to cell pellets, and RNA extraction was performed using RNeasy Mini Kit (QIAGEN). qRT-PCR was performed as described above.

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

Different statistical analyses were performed and are specified in the corresponding results in the main text or in figure legends when describing the analysis, such as Fisher's exact test ([Figure 2](#fig2){ref-type="fig"}C, main text), Wilcoxon test for unpaired samples ([Figure 1](#fig1){ref-type="fig"}B, figure legend), Wilcoxon signed-rank test ([Figures 1](#fig1){ref-type="fig"}A, 1D, and 1E, figure legend), Wilcoxon signed-rank test for paired samples ([Figure 1](#fig1){ref-type="fig"}F, figure legend). Significance was generally defined as ^∗^P≤0.01, ^∗∗^P≤0.001, while *P* \< 0.0001 was also indicated where applicable. The number of samples (*n*) used for all comparisons is indicated in the figure legends as well as in the main text. Briefly, samples from 53 individuals with 1° and 46 individuals with 2° dengue were used for comparisons presented in [Figures 1](#fig1){ref-type="fig"}A--1C. Samples from 22 paired PBMC and plasma samples were used in [Figures 1](#fig1){ref-type="fig"}D and 1E. Samples from 12 paired PBMC and plasma samples were used in [Figure 1](#fig1){ref-type="fig"}F. Samples from 68 PBMC and 31 plasma samples were used in [Figures 2](#fig2){ref-type="fig"}A--2D. In [Figure 2](#fig2){ref-type="fig"}E, 690 full-length DENV-3 genomes were analyzed. Data from 8 PBMC/plasma samples (*prM/M* hotspot) and 39 PBMC/plasma samples (*E* hotspot) are shown in [Figure 3](#fig3){ref-type="fig"}. Data from 2 independent experiments were used in [Figure 4](#fig4){ref-type="fig"}.

Data and Software Availability {#sec3.6}
------------------------------

Fastq files for all the sequences generated in this study have been deposited into NCBI\'s Sequence Read Archive, and can be accessed using BioProject ID PRJNA394021.
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